Brief: Theratechnologies Inc Confirmed That Amended Protocol For Phase 1 Clinical Trial Studying Sudocetaxel Zendusortide Has Been Filed With U.S. FDA
09/05/2023 17:05
May 9 (Reuters) - Theratechnologies Inc:
* THERATECHNOLOGIES INC - CONFIRMED THAT AMENDED PROTOCOL
FOR
PHASE 1 CLINICAL TRIAL STUDYING SUDOCETAXEL ZENDUSORTIDE HAS
BEEN FILED WITH U.S. FDA
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process